Abstracts tagged "Biologics"

Abstract Number: 1186 • 2018 ACR/ARHP Annual Meeting
Comparison of Biologic Discontinuation in Patients with Elderly-Onset Vs Younger-Onset Rheumatoid Arthritis
Michael Richter¹, Eric L. Matteson², John M. Davis III², Sara J. Achenbach³ and Cynthia S. Crowson³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Several studies have suggested that patients with elderly-onset rheumatoid arthritis (EORA) receive biologic treatments less frequently than patients with younger-onset RA (YORA). This has…
Abstract Number: 2206 • 2018 ACR/ARHP Annual Meeting
Joint Repair While Initiating Biologic Therapy in Rheumatoid Arthritis
Scott Brunet^1,2,3, Sarah Manske^1,2,3, Klaus Engelke^4,5, Steven K. Boyd^1,2,3 and Cheryl Barnabe^2,6, ¹Biomedical Engineering, University of Calgary, Calgary, AB, Canada, ²McCaig Institute for Bone and Joint Health, Calgary, AB, Canada, ³Department of Radiology, University of Calgary, Calgary, AB, Canada, ⁴Institute of Medical Physics, University of Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Medicine, Erlangen University Hospital, Erlangen, Germany, ⁶Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Functional decline and reduced quality of life for patients with rheumatoid arthritis (RA) results from chronic changes to joints in patients, including bone erosions…
Abstract Number: 2591 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Secukinumab in Axial Spondyloarthritis: First Year Data from the Czech National Registry
Herman F Mann¹, Jakub Zavada², Lucie Nekvindová³, Zlatuse Kristkova³, Pavel Horák⁴, Jiri Vencovsky¹ and Karel Pavelka², ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Ltd., spinoff company of Masaryk University, Brno, Czech Republic, ⁴IIIrd Department of internal Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with axial spondyloarthritis (AxSpA). This situation changed when anti-interleukin-17A…
Abstract Number: 552 • 2018 ACR/ARHP Annual Meeting
Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-
Kosuke Ebina¹, Makoto Hirao², Motomu Hashimoto³, Wataru Yamamoto⁴, Akira Onishi⁵, Toru Hirano⁶, Ryota Hara⁷, Masaki Katayama⁸, Shuzo Yoshida⁹, Koji Nagai⁹, Yonsu Son¹⁰, Hideki Amuro¹⁰, Kengo Akashi¹¹, Koichi Murata³, Kosaku Murakami¹², Keiichi Yamamoto¹³ and Hideki Yoshikawa¹⁴, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, ⁷The Center for Rheumatic Diseases, Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Japan, ⁸Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁹Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan, ¹⁰First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ¹¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ¹²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹³Department of Medical Statistics, Osaka City University, Osaka, Japan, ¹⁴Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Drug tolerability indicates both the patient’s and doctor’s satisfaction and useful summary measure of overall treatment effectiveness and toxicity. Although more than 5 years…
Abstract Number: 1224 • 2018 ACR/ARHP Annual Meeting
High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment
Konstantinos Thomas¹, Anastasia Makris¹, Christina Tsalapaki¹, Argyro Lazarini¹, Kalliopi Klavdianou¹, Katerina Antonatou¹, Christos Koutsianas¹, Chrisoula Hatzara¹, Emilia Hadziyannis¹ and Dimitrios Vassilopoulos², ¹Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ²Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General HospitalMedicine, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Background/Purpose: Baseline screening for tuberculosis (TB) with tuberculin skin testing (TST) and/or interferon-gamma release assays (IGRAs) is recommended for all rheumatic patients starting biologic DMARDs…
Abstract Number: 2425 • 2018 ACR/ARHP Annual Meeting
The Impact of Biologic Treatment for Rheumatoid Arthritis Patients Who Hope to Conceive
Hiromi Shimada, Taichi Miyagi, Mikiya Kato, Risa Wakiya, Shusaku Nakashima, Tomohiro Kameda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Previous reports revealed that it was difficult for rheumatoid arthritis (RA) patients to conceive1). Age, nulliparity, disease activity, NSAIDs, corticosteroid was known as the…
Abstract Number: 2592 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry
Herman F Mann¹, Jakub Zavada², Lucie Nekvindová³, Zlatuse Kristkova³, Pavel Horák⁴, Jiri Vencovsky¹ and Karel Pavelka², ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Ltd., spinoff company of Masaryk University, Brno, Czech Republic, ⁴IIIrd Department of internal Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with psoriatic arthritis (PsA). This situation changed when anti-interleukin-17A…
Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Young Mo Kang², Wan-Hee Yoo³, Paul Emery⁴, Michael E Weinblatt⁵, Edward C. Keystone⁶, Mark C. Genovese⁷, Gihyun Myung⁸, Evelyn Hong⁸, Inyoung Baek⁸ and Jeehoon Ghil⁸, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ³Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), ⁴University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Stanford University Medical Center, Palo Alto, CA, ⁸Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…
Abstract Number: 1386 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)
Christian Dejaco¹, Thomas Mueller², Omid Zamani, MD³, Ulrike Kurtz, MD⁴, Stefan Egger, MD⁵, Johannes Resch Passini, MD⁶, Anna Totzauer, MD⁷, Wolfgang Eisterer⁸, Babak Yazdani-Biuki, MD, Univ.Doc.⁹, Thomas Schwingenschloegl, MD¹⁰, Peter Peichl, MD. Univ.Doc. Msc¹¹, Angelika Kraus¹², Gerhard Naerr, PhD¹³ and Verena Rickert, MD. MBA¹⁴, ¹Rheumatology and Immunology, Medical University Graz, Graz, Austria, ²Private Office Dr. Thomas Mueller, Graz, Austria, ³Rheuma Zentrum Favoriten, Vienna, Austria, ⁴Rheuma Praxis Dr. Kurtz, Gleisdorf, Austria, ⁵Ordination Gesundheitsquadrat, Vienna, Austria, ⁶Rheumatology Department, Rheuma-Zentrum Wien-Oberlaa GmbH, Vienna, Austria, ⁷Private Office Dr. Anna Totzauer, Gmuend, Austria, ⁸Department of Hematology and Internal Oncology, KLINIKUM- KLAGENFURT am WÖRTHERSEE, Klagenfurt, Austria, ⁹Dr. Schrenk & Dr. Yazdani-Biuki OG - Gruppenpraxis, Fuerstenfeld, Austria, ¹⁰Private Office Dr. Thomas Schwingenschloegl, Wiener Neudorf, Austria, ¹¹Private Office Prim. Univ. Doz. Dr. Peter Peichl, MSc, Vienna, Austria, ¹²Private Office, Private Office Angelika Kraus, Melk, Austria, ¹³Medical Affairs, Merck Sharp & Dohme GmbH, Vienna, Austria, ¹⁴Medical Affairs, Merck Sharp&Dohme GmbH, Vienna, Austria
Background/Purpose: Golimumab has shown clinical efficacy and tolerability within its clinical trial program. No systematic outcome data regarding patient‐reported outcomes and health economic parameters reflecting…
Abstract Number: 2444 • 2018 ACR/ARHP Annual Meeting
The Risk of Solid Cancers in Patients with Rheumatoid Arthritis Exposed to Biologic Dmards with/without Prior Cancers
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan
Background/Purpose: To compare the risk of solid cancer in patient with rheumatoid arthritis treated with biologic disease modifying antirheumatic drugs(b-DMARDs) to that in patients treated…
Abstract Number: 2603 • 2018 ACR/ARHP Annual Meeting
Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
Jeffrey Crowley¹, Kim A Papp², Chih-ho Hong³, Jeff Parno⁴, Alan M Mendelsohn⁴, Qing Li⁵ and Nicole Cichanowitz⁵, ¹Bakersfield Dermatology, Bakersfield, CA, ²Probity Medical Research, Waterloo, ON, Canada, ³University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, BC, Canada, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁵Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development,…
Abstract Number: 560 • 2018 ACR/ARHP Annual Meeting
Impact of Formulary Copayment Change on Treatment Patterns in Rheumatoid Arthritis Patients on Etanercept
Hafiz Oko-osi¹, Machaon Bonafede², Mahdi Gharaibeh¹, Janna Manjelievskaia², Lorena Lopez-Gonzalez², David H. Collier¹ and Bradley S. Stolshek¹, ¹Amgen Inc., Thousand Oaks, CA, ²IBM Watson Health, Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease that requires long-term treatment to improve or maintain disease activity. Tumor necrosis factor inhibitors (TNFi), a…
Abstract Number: 1480 • 2018 ACR/ARHP Annual Meeting
Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database
Eishi Uechi^1,2 and Kiyohide Fushimi², ¹Division of Rheumatology, Tomishiro Central Hospital, Okinawa, Japan, ²Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Background/Purpose: Pneumonia is the leading cause of mortality in RA patients. No research has been conducted on the prognosis of pneumonia in RA patients. This…
Abstract Number: 2452 • 2018 ACR/ARHP Annual Meeting
Incidence Rate and Clinical Characteristics of Herpes Zoster Infection in Korean Patients with Rheumatoid Arthritis Patients
Su-Jin Moon¹, Min Jung Kim², Sun Kyung Lee², So Hee Oh², Hyoun-Ah Kim³ and Kichul Shin⁴, ¹Bucheon St. Mary's Hospital, Division of rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Bucheon, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Herpes zoster (HZ) infection is not uncommon in rheumatoid arthritis (RA) patients, especially in those treated with biologic or targeted synthetic (bts) disease-modifying antirheumatic…
Abstract Number: 2605 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson², Michael J. Nissen³, Eirik K Kristianslund⁴, Maria José Santos⁵, Kari Eklund⁶, Ziga Rotar⁷, Björn Gudbjornsson⁸, Fatos Onen⁹, Catalin Codreanu¹⁰, Ulf Lindström¹¹, Cem Gabay³, Tore Kvien⁴, Anabela Barcelos⁵, Kalle Aaltonen⁶, Matija Tomšič⁷, Thorvardur Love⁸, Gerçek Can⁹, Ruxandra Ionescu¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Karel Pavelka¹², Marleen van de Sande¹³, Irene van der Horst-Bruinsma¹⁴, Juan J. Gomez-Reino¹⁵, Carlos Sánchez-Piedra¹⁶, Gary J Macfarlane¹⁷, Florenzo Iannone¹⁸, Lise Hyldstrup¹, Niels Steen Krogh¹⁹, Mikkel Østergaard¹ and Merete Lund Hetland¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Gothenburg, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ⁸ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ⁹TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ¹⁰RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ¹¹ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Amsterdam, Netherlands, ¹⁴ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁵BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁶BIOBASADER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁷BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁸GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁹ZiteLab ApS, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 13,170 patients with psoriatic arthritis treated in routine care – pooled data from the EuroSpA Research…

« Previous Page
1
…
3
4
5
6
7
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].